260 related articles for article (PubMed ID: 11577350)
1. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.
Stanislawski T; Voss RH; Lotz C; Sadovnikova E; Willemsen RA; Kuball J; Ruppert T; Bolhuis RL; Melief CJ; Huber C; Stauss HJ; Theobald M
Nat Immunol; 2001 Oct; 2(10):962-70. PubMed ID: 11577350
[TBL] [Abstract][Full Text] [Related]
2. Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.
Voss RH; Kuball J; Engel R; Guillaume P; Romero P; Huber C; Theobald M
Immunol Res; 2006; 34(1):67-87. PubMed ID: 16720899
[TBL] [Abstract][Full Text] [Related]
3. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
[TBL] [Abstract][Full Text] [Related]
4. Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes.
Bendle GM; Holler A; Pang LK; Hsu S; Krampera M; Simpson E; Stauss HJ
Cancer Res; 2004 Nov; 64(21):8052-6. PubMed ID: 15520215
[TBL] [Abstract][Full Text] [Related]
5. Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man.
Lotz C; Ferreira EA; Drexler I; Mutallib SA; Huber C; Sutter G; Theobald M
Int J Cancer; 2004 Feb; 108(4):571-9. PubMed ID: 14696122
[TBL] [Abstract][Full Text] [Related]
6. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
7. Redirecting T cell specificity by TCR gene transfer.
Moss PA
Nat Immunol; 2001 Oct; 2(10):900-1. PubMed ID: 11577342
[No Abstract] [Full Text] [Related]
8. Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL.
Lotz C; Mutallib SA; Oehlrich N; Liewer U; Ferreira EA; Moos M; Hundemer M; Schneider S; Strand S; Huber C; Goldschmidt H; Theobald M
J Immunol; 2005 Jul; 175(2):1301-9. PubMed ID: 16002735
[TBL] [Abstract][Full Text] [Related]
9. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
10. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
11. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
[TBL] [Abstract][Full Text] [Related]
12. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.
Kuball J; Schuler M; Antunes Ferreira E; Herr W; Neumann M; Obenauer-Kutner L; Westreich L; Huber C; Wölfel T; Theobald M
Gene Ther; 2002 Jul; 9(13):833-43. PubMed ID: 12080377
[TBL] [Abstract][Full Text] [Related]
13. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
14. Targeting p53, hdm2, and CD19: vaccination and immunologic strategies.
Voss RH; Lotz C; Cellary A; Theobald M
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S43-5. PubMed ID: 10933187
[TBL] [Abstract][Full Text] [Related]
15. WT1-targeted immunotherapy of leukaemia.
Xue S; Gao L; Gillmore R; Bendle G; Holler A; Downs AM; Tsallios A; Ramirez F; Ghani Y; Hart D; Alcock S; Tranter A; Stauss HJ; Morris E
Blood Cells Mol Dis; 2004; 33(3):288-90. PubMed ID: 15528146
[TBL] [Abstract][Full Text] [Related]
16. A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model.
Sher YP; Lin SI; Chen IH; Liu HY; Lin CY; Chiang IP; Roffler S; Chen HW; Liu SJ
Oncotarget; 2016 Jan; 7(1):671-83. PubMed ID: 26621839
[TBL] [Abstract][Full Text] [Related]
17. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
18. Incomplete tolerance to the tumour-associated antigen MDM2.
Ramírez F; Ghani Y; Stauss H
Int Immunol; 2004 Feb; 16(2):327-34. PubMed ID: 14734618
[TBL] [Abstract][Full Text] [Related]
19. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1.
Shirai M; Arichi T; Nishioka M; Nomura T; Ikeda K; Kawanishi K; Engelhard VH; Feinstone SM; Berzofsky JA
J Immunol; 1995 Mar; 154(6):2733-42. PubMed ID: 7533182
[TBL] [Abstract][Full Text] [Related]
20. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein.
Dahl AM; Beverley PC; Stauss HJ
J Immunol; 1996 Jul; 157(1):239-46. PubMed ID: 8683121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]